Diabetes

An international BMJ panel recommended broader use of SGLT-2 inhibitors and GLP-1 receptor agonists.

The sensor detects acetone levels in the breath to indicate diabetes.

Simplifying complex information through illustrations and storytelling helps patients feel that managing their condition is achievable.

New research uncovers a pathway linking diabetes and heightened blood clot risks, paving the way for innovative treatments to prevent cardiovascular complications.

The number of patients prescribed SGLT2 inhibitors is growing.

Pharmacists help connect patients with the correct resources and help remove barriers so patients can receive continuous care.

Pharmacists can educate patients and health care professionals in addition to coordinating lab orders, interpreting results, and guiding patients through the next steps.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, explains the different stages of type 1 diabetes, teplizumab’s use, and emphasizes the pharmacist’s role in care.

Pharmacists should consider GLP-1 receptor agonists as second-line agents in older adults with DKD when additional glycemic control is needed.

Researchers reveal that saliva tests for insulin levels offer a noninvasive method to predict type 2 diabetes and obesity risks effectively.

Amy C. Nieto explains essential guidelines for managing diabetes during Ramadan, ensuring safe fasting practices and optimal health for patients.

A new study reveals that individuals with type 2 diabetes (T2D) face significant financial hardships, impacting their health and medication adherence.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses the expanding role of GLP-1 receptor agonists in holistic type 2 diabetes care, highlighting their cardio-renal-hepatic benefits, clinical access challenges, emerging investigational therapies, and practical strategies for individualized, guideline-based prescribing.

GLP-1 receptor agonists show promise in improving survival rates for older patients with cancer who have type 2 diabetes (T2D), highlighting their potential in oncology.

Insights from the American Diabetes Association 85th Scientific Sessions.

Pharmacists are pivotal in optimizing GLP-1 receptor agonist therapy.

Critically ill patients treated with a pharmacist-managed insulin protocol achieved higher rates of glucose control than those treated with conventional methods.

Different dietary strategies, including intermittent energy restriction, enhance weight loss and blood sugar control in those with type 2 diabetes (T2D) and obesity.

Once-weekly efsitora alfa shows promising hemoglobin A1C reduction in type 2 diabetes (T2D), simplifying insulin therapy and reducing injection frequency significantly.

Obesity and type 2 diabetes in youth significantly increase the risk of osteoporosis and fractures, highlighting the need for early intervention and healthy habits.

Finerenone emerges as a promising treatment for patients with diabetes and chronic kidney disease, significantly reducing cardiovascular and renal risks.

A maternal inflammatory diet during pregnancy raises the risk of offspring developing type 1 diabetes, highlighting the impact of nutrition on early health.

GLP-1 medications like semaglutide face scrutiny over compounded versions, raising concerns about patient safety and counterfeit products in diabetes treatment.

Simplifying complex information through illustrations has consistently helped patients feel that managing type 1 diabetes is achievable.

As compounded medications gain popularity amid drug shortages, concerns about safety, quality, and regulation have intensified, making Pharmacy Compounding Accreditation Board (PCAB) accreditation a safeguard for consistency, oversight, and public trust in compounding pharmacy practices.